OncoMatch/Clinical Trials/NCT05325632
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Is NCT05325632 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including HER-2 pulsed DC1 and Trastuzumab for her2-positive breast cancer.
Treatment: HER-2 pulsed DC1 · Trastuzumab · Pertuzumab · Paclitaxel — The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (HER2+ (per ASCO/CAP criteria))
HER2+ (per ASCO/CAP criteria) invasive carcinoma of the breast
Disease stage
Required: Stage I, II, III
clinical stage I- III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Patients may not be receiving any other investigational agents for the treatment of their breast cancer.
Lab requirements
Blood counts
normal organ and marrow function as defined per protocol
Kidney function
normal organ and marrow function as defined per protocol
Liver function
normal organ and marrow function as defined per protocol
Cardiac function
Cardiac ejection fraction within institutional normal limits by either Multigated Acquisition Scan (MUGA) or Echocardiogram at baseline.
Participants must have normal organ and marrow function as defined per protocol. Cardiac ejection fraction within institutional normal limits by either Multigated Acquisition Scan (MUGA) or Echocardiogram at baseline.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05325632 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages